Linked Life Data

20400905

Source:http://linkedlifedata.com/resource/pubmed/id/20400905

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-6-17
pubmed:abstractText
The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P < or = 0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-12877398, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-14399272, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-15729083, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-16001092, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-16086624, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-16946178, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-17217921, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-17284130, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-18172020, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-18501261, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-19032701, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-19606237, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-3290940, http://linkedlifedata.com/resource/pubmed/commentcorrection/20400905-9376453
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1473-5857
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
214-7
pubmed:dateRevised
2011-8-1
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
pubmed:affiliation
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural